News
Public · Published
Acrivon to Present Late-Breaking Oral Plenary Presentation and Posters at the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
Acrivon Therapeutics announced that it will present research at the EORTC-NCI-AACR cancer symposium in Barcelona, November 18–20, 2026. The program includes a late-breaking oral presentation on safety, dose optimization, and preliminary antitumor activity in a Phase 1 study of ACR-2316, plus poster presentations.
Published:
Updated:
What happened
Acrivon Therapeutics announced that it will present research at the EORTC-NCI-AACR cancer symposium in Barcelona, November 18–20, 2026. The program includes a late-breaking oral presentation on safety, dose optimization, and preliminary antitumor activity in a Phase 1 study of ACR-2316, plus poster presentations.
Confirmed
Global impact / market context
The presentations may give investors more information about ACR-2316, an experimental drug, including early safety and activity findings. If later evidence supports further development, that could shape Acrivon’s research spending and prospects for future revenue; the article provides no results or commercial outlook yet.
Analyst inference
This is a planned scientific disclosure, not a report of a treatment approval or established patient benefit. The Phase 1 study is an early human-testing stage, so preliminary findings may inform later research but do not establish whether ACR-2316 works or can be sold.
Analyst inference
What to watch
- Watch for the November 20 oral presentation’s reported safety, dose optimization, and preliminary antitumor activity findings from the Phase 1 ACR-2316 study. Confirmed
- The company says copies of the presentations will be available on its website after the symposium presentations; check whether those materials add study details. Confirmed
- Any favorable early findings could support continued development, while safety concerns or limited activity could require changes in research plans and spending. Analyst inference